Cycle Regulation and Fertility

"Regulates your cycle" and "supports fertility" are the two phrases that sell the most chasteberry, and they are the two where the gap between the marketing and the evidence is widest. That is not because the idea is silly — it follows logically from the herb's mechanism, and there is one decent trial behind it. It is because the whole claim rests on a single small randomised study from 1993, in 37 analysable women, and everything built on top of that is extrapolation.

This article walks through what the cycle-regulation claim actually means physiologically, what the Milewicz trial showed, why the fertility evidence is confounded almost beyond rescue by multi-ingredient products, and where the mechanism simply runs out — PCOS and menopause. It ends with the part that matters most in practice: what an irregular cycle deserves before anyone reaches for a bottle.

Table of Contents

1. What "Regulating the Cycle" Actually Means
2. The Luteal Phase and Why Prolactin Matters
3. The Milewicz Trial: The One Real Study
4. Irregular Cycles, Spotting and Amenorrhoea
5. Fertility: The Honest Reading
6. PCOS: Not the Herb for It
7. Menopause: Where the Mechanism Runs Out
8. Before You Self-Treat: What an Irregular Cycle Deserves
9. Contraception, IVF and Trying to Conceive
10. The Verdict, Stated Plainly
11. Key Research Papers
12. Connections

What "Regulating the Cycle" Actually Means

"Cycle regulation" is a marketing phrase that covers at least five different physiological problems, and chasteberry has plausible relevance to exactly one of them.

The honest version of the claim, then, is narrow: chasteberry has been shown to help a short or under-performing luteal phase caused by latent hyperprolactinaemia. That is a specific, testable situation. It is not "irregular periods" in general.

The Luteal Phase and Why Prolactin Matters

After ovulation, the collapsed follicle reorganises into the corpus luteum, a temporary endocrine gland whose job is to make progesterone for about 14 days. Progesterone converts the oestrogen-primed uterine lining into a secretory, receptive tissue capable of supporting an implanting embryo. If no pregnancy occurs, the corpus luteum winds down, progesterone falls, and the lining sheds.

A luteal phase defect means that machinery underperforms — the phase runs short (classically under 11 days), or progesterone output is inadequate, or both. Clinically it can show up as premenstrual spotting, a short overall cycle, or difficulty conceiving or holding an early pregnancy. It is worth saying that luteal phase defect is a contested diagnosis in reproductive medicine: it is hard to define, hard to measure reproducibly with single progesterone draws, and reproductive-medicine bodies have questioned whether it stands as an independent cause of infertility at all. That controversy sits underneath everything in this section.

Where does prolactin come in? Prolactin's normal job is lactation, and it is deliberately antagonistic to reproduction — that is why breastfeeding suppresses fertility. Raised prolactin suppresses hypothalamic GnRH pulses, which blunts LH and FSH, which impairs follicle development, ovulation and corpus luteum function. Even mild excess can flatten the luteal phase.

Latent hyperprolactinaemia is the specific target here: resting prolactin is normal on a routine blood test, but the pituitary over-releases prolactin when provoked — classically by intravenous thyrotropin-releasing hormone (TRH). The interpretation is that the dopamine brake is weak, so the system has too little reserve. That is precisely what a mild dopamine-mimicking herb might correct, and it is what the one good trial set out to test. A caveat for readers in 2020s clinical settings: TRH stimulation testing has largely fallen out of routine practice, so "latent hyperprolactinaemia" is a diagnosis you are unlikely to be given today. The trial is real; the diagnostic category it used is dated.

The Milewicz Trial: The One Real Study

Published in German in Arzneimittel-Forschung in 1993, this is the study every "chasteberry regulates your cycle" claim ultimately cites. Its details deserve to be known rather than paraphrased.

• Design: randomised, double-blind, placebo-controlled.
• Participants: 52 women with luteal phase defects attributed to latent hyperprolactinaemia. 37 complete case reports were statistically evaluated — 17 on chasteberry, 20 on placebo. That is a substantial dropout, and it means the analysed sample is genuinely small.
• Intervention: one 20 mg capsule daily of a Vitex agnus castus preparation, or placebo, for three months.
• Measurements: blood drawn on days 5–8 and day 20 of the cycle, before and after treatment. Latent hyperprolactinaemia was assessed by measuring prolactin release 15 and 30 minutes after intravenous injection of 200 µg TRH.
• Results, active group only: TRH-stimulated prolactin release was reduced; shortened luteal phases were normalised; deficits in luteal progesterone synthesis were eliminated. Luteal 17β-oestradiol rose. All other hormonal parameters were unchanged. These changes were significant and occurred only in the verum group.
• Safety and an incidental finding: no side effects were seen, and two women in the chasteberry group became pregnant during the study.

What makes this study valuable is that it is not a symptom questionnaire. It measured hormones, and the pattern it found is internally coherent: reduce the prolactin over-response, and the luteal phase lengthens and its progesterone output recovers. That is the mechanism doing exactly what the mechanism predicts. The Planta Medica systematic review counted this as one of only two randomised trials in latent hyperprolactinaemia, and summarised it as showing chasteberry superior to placebo for reducing TRH-stimulated prolactin, normalising a shortened luteal phase, and raising mid-luteal progesterone and 17β-oestradiol.

What keeps it from being decisive is everything else. Thirty-seven analysable women. One trial. 1993. German-language. Never replicated. The two pregnancies are an anecdote inside a study that was not designed or powered to measure conception. And the diagnostic entry criterion — TRH-stimulated latent hyperprolactinaemia — is one modern clinics rarely apply, so it is genuinely unclear who today corresponds to the women who were enrolled.

Irregular Cycles, Spotting and Amenorrhoea

Beyond luteal phase defect, chasteberry's traditional reputation extends to amenorrhoea, oligomenorrhoea and premenstrual spotting. The German Commission E — the expert body that reviewed herbal medicines for the former German health authority — approved chasteberry for irregularities of the menstrual cycle, premenstrual disturbances and mastodynia. That approval is often quoted as though it were a clinical trial result. It is not. Commission E monographs were expert consensus based on the evidence available in the 1980s, and the cycle-irregularity indication rests mostly on traditional and observational use rather than randomised data.

The systematic reviews are the corrective here. When van Die and colleagues went looking for randomised controlled trials of chasteberry in women's health, they found twelve usable trials: eight in PMS, two in PMDD, and two in latent hyperprolactinaemia. Not one randomised trial of chasteberry for amenorrhoea, oligomenorrhoea, heavy bleeding or dysmenorrhoea as a primary endpoint. The absence is the finding.

So the honest framing for someone with irregular cycles is this. If your cycles are irregular and the cause has been worked up and the answer is mild prolactin excess with luteal insufficiency, chasteberry has one supporting trial. If the cause has not been established, taking chasteberry is treating a symptom whose origin you do not know — and some of the possible origins matter a great deal.

Fertility: The Honest Reading

The fertility claim is an extension of the luteal-phase story: if mild prolactin excess is shortening the luteal phase, and a shortened luteal phase makes implantation harder, then lowering prolactin might help conception. It is a reasonable chain of reasoning. The problem is that nobody has properly tested it.

The most-cited human data come from FertilityBlend, and they illustrate the confounding problem perfectly. Westphal and colleagues (Clinical and Experimental Obstetrics and Gynecology, 2006) ran a double-blind, placebo-controlled study of a proprietary nutritional supplement in 93 women aged 24–42 who had been trying to conceive for six to 36 months. After three months, mid-luteal progesterone showed a trend upward overall and rose significantly in women whose baseline mid-luteal progesterone was under 9 ng/ml; luteal-phase basal temperature days increased; both short (< 27 days) and long (> 32 days) cycles normalised. Fourteen of 53 women on the supplement conceived (26 percent) versus four of 40 on placebo (10 percent), p = 0.01. A 2004 pilot by the same group pointed the same way.

That is a real, statistically significant result — and it says almost nothing about chasteberry. FertilityBlend is chasteberry plus green tea, L-arginine, folate, other vitamins and minerals. L-arginine and folate have their own reproductive rationales. There is no arm isolating chasteberry, no dose of chasteberry disclosed in a way you could match, and no way to apportion the effect. The authors themselves concluded only that "nutritional supplements could provide an alternative or adjunct to conventional fertility therapies."

Older European studies of the combination product Mastodynon (which contains chasteberry alongside several homeopathic constituents) in female infertility exist in the literature, and they have the same problem magnified: a multi-ingredient preparation, small numbers, mostly German-language, and designs that predate modern reporting standards.

Add the two incidental pregnancies in the Milewicz trial and you have the entire honest case. The bottom line: chasteberry is not an established fertility treatment. It may be a defensible option for a documented, mild, prolactin-related luteal problem. It is not a substitute for a fertility evaluation, and it does nothing for the causes that actually dominate the infertility clinic — tubal disease, endometriosis, male-factor infertility, diminished ovarian reserve, and anovulation from PCOS. If you have been trying for twelve months (or six months over the age of 35), the correct next step is an evaluation, not a supplement.

PCOS: Not the Herb for It

Chasteberry appears constantly in PCOS supplement blends, and the pairing does not hold up.

Polycystic ovary syndrome is driven by hyperandrogenism and, in most cases, insulin resistance, producing irregular or absent ovulation, acne, hirsutism and metabolic consequences. Prolactin is not the problem — and this matters, because mildly raised prolactin is sometimes found alongside PCOS, which has led to a lot of loose reasoning. Current diagnostic frameworks treat hyperprolactinaemia as a condition to be excluded before PCOS is diagnosed, precisely because they are different things.

There is no adequately designed randomised trial of chasteberry alone for PCOS. What exists is chasteberry as an ingredient in multi-herb PCOS formulas, which cannot attribute an effect, and the general argument that "it regulates cycles." Set against the interventions with real evidence in PCOS — weight management where relevant, metformin, inositol, letrozole for ovulation induction, combined hormonal contraception for cycle control and androgen symptoms — a dopaminergic herb aimed at a hormone that is not the driver is a poor use of time and money. If your cycles are irregular from PCOS, chasteberry is not the tool.

Menopause: Where the Mechanism Runs Out

Chasteberry sits in a great many "menopause support" formulas, usually next to black cohosh. The biology argues against it.

Chasteberry works by modulating prolactin and thereby the luteal phase of an ovulating cycle. After menopause there is no ovulation, no corpus luteum and no luteal phase — there is nothing left for the mechanism to act on. And the defining menopausal symptoms, hot flushes and night sweats, are vasomotor events driven by oestrogen withdrawal acting on hypothalamic thermoregulation, not by prolactin.

The evidence matches the reasoning: there is little direct trial support for chasteberry alone in menopausal symptoms, and where it appears in the menopause literature it is usually inside combination products with black cohosh or other herbs, which cannot isolate its contribution. A dedicated review of chasteberry in menopause-related complaints exists and is worth reading precisely because of how thin the material is.

The one nuance worth keeping: in perimenopause, cycles still happen — erratically — and premenstrual symptoms often intensify. To the extent perimenopausal complaints are cyclical PMS-type symptoms rather than vasomotor ones, the PMS evidence may partly apply. Once cycles have stopped, it does not.

Before You Self-Treat: What an Irregular Cycle Deserves

This is the most useful section on the page, because it is the step people skip.

An irregular cycle is a signal, and the causes range from trivial to serious. A reasonable first-line work-up, which any primary care clinician can order, typically includes:

1. A pregnancy test. First, always, regardless of how confident you are.
2. Thyroid function (TSH, and free T4 if abnormal). Hypothyroidism is a common, easily fixed cause of both irregular cycles and raised prolactin — a high TRH drive stimulates prolactin release as well as TSH. Treat the thyroid and the prolactin often normalises.
3. Prolactin. Drawn without prior nipple stimulation, strenuous exercise or a stressful venepuncture, all of which transiently raise it. If it comes back high, the follow-up questions are: is it macroprolactin (an inert antibody-bound form that inflates the assay in a well person)? Is it a medication? How high is it?
4. Androgens and a PCOS assessment where there are features suggesting it — total and free testosterone, sometimes DHEAS and 17-hydroxyprogesterone, plus pelvic ultrasound.
5. FSH, LH and oestradiol where premature ovarian insufficiency or hypothalamic amenorrhoea is possible.
6. A medication review. Antipsychotics, metoclopramide, domperidone, some antidepressants, opioids and verapamil all raise prolactin. This is a common and entirely reversible cause.
7. Pituitary imaging when prolactin is persistently and substantially elevated with no drug or thyroid explanation — to look for a prolactinoma.

Endocrine society guidance for hyperprolactinaemia follows essentially this sequence, and the reason it exists is that the answers change the treatment completely. A prolactinoma is treated with a dopamine agonist and monitored with imaging. Hypothyroidism is treated with levothyroxine. Drug-induced hyperprolactinaemia is managed by reviewing the drug with the prescriber. None of these is a situation where an over-the-counter herb is the right response, and in the first case a herb that partially lowers prolactin could mask the very number being used to monitor a tumour.

Contraception, IVF and Trying to Conceive

• Hormonal contraception. Genuinely uncertain. The best data point is incidental: in the Berger study, 13 of 43 participants were taking oral contraceptives, and no difference in response was seen between those on and off the pill. That is reassuring at the level of "chasteberry did not obviously stop working," but it was not designed as an interaction study and it does not tell you whether chasteberry affects contraceptive efficacy. It almost certainly does not act as a contraceptive itself, and it should never be relied upon as one.
• IVF and stimulated cycles. Avoid unless your fertility specialist has explicitly approved it. Assisted reproduction cycles are precisely choreographed with gonadotropins, agonists or antagonists, and trigger injections. Adding an unquantified agent that acts on pituitary dopamine receptors introduces an uncontrolled variable into a protocol built on control — and it may complicate the interpretation of monitoring bloods.
• Trying to conceive naturally. Stop chasteberry as soon as you might be pregnant. The pregnancy safety review found only theoretical and in-vitro evidence — suggestions of oestrogenic, progesteronic and uterine-stimulant activity — with no adequate human safety data, and noted explicitly that women of childbearing age may take it while unknowingly pregnant. The practical rule: if you are actively trying, either do not take it, or stop at the point a period is late.
• Breastfeeding. Avoid. Prolactin makes milk; chasteberry lowers prolactin. Traditional sources pointed both ways and the systematic review found expert opinion in outright conflict, which is itself a reason to stay away when milk supply matters.

The Verdict, Stated Plainly

Chasteberry has one supporting randomised trial for cycle regulation, in a narrowly defined group — women with a short luteal phase attributable to latent hyperprolactinaemia — using a diagnostic test that has largely gone out of use. The trial's findings were coherent and biologically sensible, and it has never been replicated. For fertility, the human evidence is a multi-ingredient supplement whose result cannot be attributed to chasteberry, plus two incidental pregnancies in a 37-woman hormone study. For PCOS and menopause, the mechanism does not point there and the evidence does not either.

That is not a reason to dismiss the herb — it is a reason to be precise about what it is for. The strong case for chasteberry lives on the PMS and cyclical breast pain page. This one is the honest inventory of everything else.

Key Research Papers

Every identifier below was checked live against NCBI E-utilities before being written; first author, title, journal and year all had to match.

Luteal phase, prolactin and cycle regulation

1. Milewicz A, Gejdel E, Sworen H, et al. [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study]. Arzneimittel-Forschung. 1993;43(7):752–756. German-language. 52 women enrolled, 37 analysed, 20 mg daily for three months; TRH-stimulated prolactin fell, luteal phases normalised, luteal progesterone recovered — in the active group only.
2. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Medica. 2013;79(7):562–575. The definitive inventory: 12 randomised trials, of which only two addressed latent hyperprolactinaemia and none addressed amenorrhoea or dysmenorrhoea.
3. Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Experimental and Clinical Endocrinology. 1994;102(6):448–454. Why the effect is specific to prolactin and leaves the gonadotropins alone.
4. Merz PG, Gorkow C, Schrödter A, et al. The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects. Experimental and Clinical Endocrinology and Diabetes. 1996;104(6):447–453. The dose-dependence that complicates simple claims: the lowest dose raised prolactin, the highest lowered it.

Fertility

1. Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clinical and Experimental Obstetrics and Gynecology. 2006;33(4):205–208. 93 women; 26 percent versus 10 percent pregnancy rate at three months — but for a chasteberry-plus-green-tea-plus-L-arginine-plus-vitamins product, not chasteberry alone.
2. Westphal LM, Polan ML, Trant AS, Mooney SB. A nutritional supplement for improving fertility in women: a pilot study. The Journal of Reproductive Medicine. 2004;49(4):289–293. The earlier pilot for the same combination product.
3. Rafieian-Kopaei M, Movahedi M. Systematic review of premenstrual, postmenstrual and infertility disorders of Vitex agnus castus. Electronic Physician. 2017;9(1):3685–3689.
4. Chasteberry, Mastodynon and female infertility — the older German-language combination-product literature. PubMed search.

Prolactin work-up and endocrine context

1. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2011;96(2):273–288. The reference sequence: confirm, exclude pregnancy, review drugs, check thyroid and renal function, consider macroprolactin, image when indicated.
2. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature Reviews Endocrinology. 2023;19(12):722–740. The current consensus on prolactinoma, and why a raised prolactin is a diagnostic question.
3. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology. 2006;65(2):265–273.

Menopause and safety in reproduction

1. van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Vitex agnus-castus (chaste-tree/berry) in the treatment of menopause-related complaints. Journal of Alternative and Complementary Medicine. 2009;15(8):853–862. A dedicated review of a thin literature.
2. Dugoua JJ, Seely D, Perri D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. Canadian Journal of Clinical Pharmacology. 2008;15(1):e74–e79. Evidence in pregnancy is theoretical and in-vitro only; expert opinion on lactation is in outright conflict.
3. Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Safety. 2005;28(4):319–332. Includes the German Commission E indications and the recommendation to avoid in pregnancy and lactation.
4. Berger D, Schaffner W, Schrader E, Meier B, Brattström A. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Archives of Gynecology and Obstetrics. 2000;264(3):150–153. The source of the only oral-contraceptive observation in this literature.

Live PubMed Searches

1. Chasteberry and luteal phase
2. Latent hyperprolactinaemia and TRH testing
3. Luteal phase deficiency — the diagnostic controversy
4. Hyperprolactinaemia — causes and evaluation
5. Macroprolactin
6. PCOS international guideline
7. Herbal medicine and IVF outcomes
8. Evaluating oligomenorrhoea

Connections

• All Herbs
• Chasteberry Benefits — the hub
• PMS and Cyclical Breast Pain — where the evidence is strongest
• Prolactin and Hormonal Mechanism — why a raised prolactin needs a diagnosis
• Forms, Dosing and Interactions
• Chasteberry (Vitex)
• Reproductive Medicine
• White Peony Root (Bai Shao) — the other herb in the menstrual-formula literature
• Dong Quai
• Black Cohosh — the menopause herb chasteberry is often bundled with

Back to Table of Contents